A plain-spoken reading desk for the tirzepatide literature — what the 2024-2025 trials actually found, walked through one step at a time.
Tirzepatide Order

Tirzepatide Side Effects: What the Research Shows

The short version

Tirzepatide side effects in clinical trials are dominated by gastrointestinal events: nausea, vomiting, diarrhoea, constipation, and decreased appetite. These are dose-related, most frequent during dose escalation, and mostly mild to moderate. A meta-analysis of nine randomised controlled trials (9,871 participants) found a significantly increased risk of the composite of gallbladder or biliary disease versus controls (relative risk 1.97) [6]. The prescribing label carries a boxed warning about thyroid C-cell tumours observed in rodent studies — unconfirmed in humans, but a contraindication for people with a personal or family history of medullary thyroid carcinoma (MTC) or MEN-2 [7]. This page summarises the tirzepatide side-effects record from the peer-reviewed literature and the FDA pharmacovigilance data. It covers the bad side effects — including gallbladder risk, lean-mass loss, and weight regain after stopping — as well as the more common GI events.

What are the side effects of tirzepatide? The trial record

The most comprehensively documented tirzepatide side effects are gastrointestinal — nausea, vomiting, diarrhoea, constipation, and decreased appetite. These were measured across all SURPASS and SURMOUNT phase 3 trials and are the primary driver of both discontinuations and the stepwise dose-escalation schedule.

A 2023 systematic review and meta-analysis (Mishra R et al., Cureus 2023) quantified the incidence of tirzepatide-induced GI manifestations across trials [8]. A 2026 pharmacovigilance analysis of FAERS (FDA Adverse Event Reporting System) data from 2022 to 2025 found injection site reactions were the second most frequently reported adverse-event category, after GI events, with over 19,000 injection-site reaction reports [9].

A 2025 meta-analysis covering GI safety of tirzepatide in people with obesity without diabetes (Safwan M et al., Ann Saudi Med 2025) estimated the overall GI adverse-event risk at approximately 2.9-fold above placebo [1].

A 2026 bibliometric and pharmacovigilance analysis of FAERS (Shen P et al., PLoS One 2026) further characterised the GI adverse-event profile with a median time to onset of approximately 16 days and most events within the first three months [9].

What are the bad side effects of tirzepatide?

The most clinically significant adverse effects in the tirzepatide literature — the ones the label, the meta-analyses, and the safety reviews flag explicitly — are:

Gallbladder and biliary disease. Nine-RCT meta-analysis (Zeng Q et al., Front Endocrinol 2023, n=9,871): relative risk 1.97 (95% CI 1.14–3.42) for the composite gallbladder-or-biliary-disease outcome versus controls [6]. A twelve-trial meta-analysis (Gong J et al., J Diabetes Investig 2025) found a comparable signal for gallbladder and biliary disease (relative risk 1.52) and cholelithiasis — gallstone formation — specifically (relative risk 1.67) [19]. Rapid weight loss is a known precipitant of gallstones (the proposed mechanism); both signals are consistent across analyses.

Thyroid C-cell tumours and MEN-2 (boxed warning). The FDA prescribing label carries a boxed warning based on rodent studies in which structurally related drugs in this class caused dose- and duration-dependent thyroid C-cell tumours. Whether this translates to humans is not established. The label contraindication is clear: the drug should not be used by people with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2 [7]. A 2026 state-of-the-art safety narrative review (Kunutsor SK et al., Drugs 2026) lists medullary thyroid carcinoma as among the rare theoretical class associations, not a demonstrated human risk [18].

Cancer risk (broader). A 2025 systematic review and meta-analysis (Park J et al., Endocrinol Metab 2025) specifically assessed cancer risk in individuals with and without diabetes treated with tirzepatide across the trial programme [20].

Lean-mass and muscle loss. Approximately 25% of weight lost in the SURMOUNT-1 DXA substudy was lean mass (Look M et al., Diabetes Obes Metab 2025) [10]. A systematic review (Batsis JA et al., Ann Intern Med 2026) placed the median muscle-attributable share of weight loss at approximately 28% across incretin trials [15]. A Diabetes Care review (Locatelli JC et al., 2024) characterised the lean-mass loss as comparable to a decade or more of ageing and recommended resistance exercise [16].

Weight regain after stopping. SURMOUNT-4 (Aronne LJ et al., JAMA 2024): participants switched to placebo after initial treatment regained weight while those continuing on treatment kept losing [14]. A post hoc analysis of the SURMOUNT-4 data (Horn DB et al., JAMA Intern Med 2026) found cardiometabolic risk factors worsened proportionally to weight regain after stopping [22].

Higher discontinuation rate versus comparators. A meta-analysis of three head-to-head trials versus another approved incretin agent (Qazi S et al., Healthcare 2026) found discontinuation due to adverse events was approximately 32% higher with tirzepatide, driven largely by GI effects [37]. A real-world FAERS analysis (Almansour HA et al., Healthcare 2025) also flagged incorrect dose administration as the single most frequently reported event, underscoring the importance of correct titration and injection technique [21].

Does tirzepatide cause diarrhea? Gastrointestinal effects in detail

Diarrhoea is one of the four main tirzepatide GI side effects, along with nausea, vomiting, and constipation. In community accounts, roughly 17–25% of users describe diarrhoea, typically peaking around day four post-injection and gradually improving with continued exposure.

A post hoc analysis from the SURPASS programme (Wharton S et al., Diabetes Obes Metab 2024) found that gastrointestinal adverse events and weight reduction were separable — weight loss occurred independently of whether GI events were experienced, indicating that the appetite-suppression and metabolic mechanisms are not merely consequences of feeling too sick to eat [35].

A 2025 analysis of GI tolerability and its relationship to weight reduction across the treatment period (Wharton S et al., Diabetes Obes Metab 2025) further characterised the temporal trajectory of GI symptoms, finding the period of greatest GI burden coincides with the titration phase and generally resolves at maintenance doses [38].

The standard clinical approach documented in the literature is the slow titration schedule: starting at 2.5 mg for four weeks before any increase, and increasing by only 2.5 mg every four weeks. That schedule is the FDA label's mechanism for reducing GI tolerability burden. Going faster is not supported by the trial protocols and would be expected to increase GI adverse-event rates.

Perioperative and drug-interaction cautions

Two additional tirzepatide side-effects cautions are worth flagging for specific situations:

Perioperative aspiration risk. The drug's approximately five-day half-life and its transient slowing of gastric emptying create a theoretical concern for retained gastric contents under sedation or general anaesthesia. A 2024 review (Jalleh RJ et al., J Clin Endocrinol Metab 2024) on the clinical consequences of delayed gastric emptying with GLP-1 receptor agonists and tirzepatide proposed prolonged fasting, point-of-care gastric ultrasound, or prokinetics around procedures [13]. Documented aspiration is rare but the mechanistic concern is well-characterised.

Oral-contraceptive reliability. The FDA prescribing label advises that tirzepatide's slowing of gastric emptying may reduce the effectiveness of oral hormonal contraceptives around dose initiation and dose increases. The label suggests a non-oral or barrier method as a supplement during those windows [7].

Dehydration and kidney risk. Severe or prolonged vomiting and diarrhoea can cause volume depletion — the proposed mechanism by which incretin therapies could precipitate acute kidney injury in people already dehydrated or on diuretics, ACE inhibitors, or ARBs. Large randomised and observational datasets have not confirmed a significant population-level increase in acute kidney injury risk and may even suggest renal benefit in high-risk groups, per the 2026 state-of-the-art safety review [18]. The risk is mechanistic and tied to severity of GI side effects rather than a demonstrated harm.